IFN

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Retrieved on: 
Wednesday, September 14, 2022
IL-27, International Cytokine & Interferon Society, The Cancer Genome Atlas, FDA, EDT, TIGIT, Neoplasm, Gene, Poster, ICIS, CD73, Surface, Cytokine, GlaxoSmithKline, Patient, PVRIG, Novartis, Radiation, IFN, Orphan drug, Fast Track, Liver, CD39, Tumor microenvironment, PD-L1, GLOBE, TCGA, Gene expression, Kidney, Type 1, CCR8, Vaccine, Palladium, Pharmaceutical industry, Cancer

CAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company will present new preclinical data on the role of IL-27 in therapy resistance at the 10th Annual Cytokines Meeting of the International Cytokine and Interferon Society (ICIS) being held September 20 – 23 at Big Island, Hawaii. The poster, entitled IL-27 Inhibits Immune Cell Reinvigoration Mediated by PD-(L)1 Blockade and Induces a Type 1 Interferon Gene Expression Signature Associated with Resistance to Therapy in Cancer Patients (#297), will first be presented in a virtual preview session today at 2:00 - 3:30 pm HST/8:00 - 9:30 pm EDT.

Key Points: 
  • We have identified an IL-27 gene signature that is enriched in several tumor types from The Cancer Genome Atlas (TCGA).
  • Interestingly, this IL-27 signature includes many interferon (IFN) stimulated genes that have been associated with resistance to therapy across different cancers.
  • These findings further bolster our belief that SRF388, a first-in-class anti-IL-27 monoclonal antibody, holds important potential in the treatment of certain cancers.
  • Furthermore, Surface Oncology has identified a potential biomarker associated with IL-27 that may be useful in helping to identify patients most likely to respond to SRF388.

Eiger BioPharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application

Retrieved on: 
Tuesday, September 6, 2022
European Medicines Agency, Mortality, Peginterferon-alfa, Congenital hyperinsulinism, COVID-19, HBV, Hospital, Obesity, Hepatitis, CV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Awareness, Degenerative disease, HCV, Death, Risk, Data monitoring committee, Incidence, IFN, Infection, Food, SEC, Kidney disease, Eiger, Cell, Investment, Progeria, HDV, Manuscript, Severe acute respiratory syndrome coronavirus 2, FDA, Therapy, Hypertension, III, Diabetes, Compte rendu, Private Securities Litigation Reform Act, COVID, Forward-looking statement, Bristol Myers Squibb, Patient, Pharmaceutical industry, Vaccine

Eiger is developing peginterferon lambda for the treatment of HDV infection.

Key Points: 
  • Eiger is developing peginterferon lambda for the treatment of HDV infection.
  • Peginterferon lambda has been administered to over 4,000 subjects in 28 clinical trials of HBV, HCV, HDV and COVID-19.
  • This evaluation of peginterferon lambda versus placebo was the second largest study to date of a COVID-19 therapeutic.
  • The primary endpoint was a clinical outcome comparing hospitalizations or emergency room visits greater than six hours after a single subcutaneous injection of peginterferon lambda versus placebo.

Rob Shema joins altafiber as Director – Government Affairs & Business Development

Retrieved on: 
Wednesday, August 24, 2022
Data Management, Technology, VoIP, Telecommunications, Mobile, Wireless, Networks, Internet, CEO, Hawaiian Telcom, Government Affairs Institute, Public affairs, Solution, Business development, IFN, Internet Authentication Service, Cincinnati metropolitan area, EVP, Independent, ONX, Human, Cincinnati Bell, Company, Marketing, Secure Access Service Edge, Comcast, CNI, Cable television

altafiber is pleased to announce that Rob Shema is joining the organization as Director Government Affairs & Business Development.

Key Points: 
  • altafiber is pleased to announce that Rob Shema is joining the organization as Director Government Affairs & Business Development.
  • Mr. Shema most recently served as CEO of Com Net (CNI) and Independents Fiber Network (IFN), headquartered in Wapakoneta, Ohio.
  • While at CNI/IFN, Mr. Shema led efforts to expand service offerings over their regional fiber network on a wholesale and commercial basis.
  • Rob also spent 9 years with Comcast in various roles (Government Affairs, Public Affairs, Marketing and Programming).

CytomX Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 4, 2022
Epithelial cell adhesion molecule, GLOBE, AbbVie, Cancer, Investment, Clinical trial, Research, Patient, Bi-specific T-cell engager, Tumor microenvironment, Nivolumab, ...Continued, TCB, Risk, NIVO, Ipilimumab, SAN, Partnership, Safety, Webcast, Nasdaq, ID, Interferon, ESMO, ADC, IFN, Preclinical development, Therapeutic index, American Association for Cancer Research, Neoplasm, Therapy, COVID-19, Program, Amgen, AACR, Triple-negative breast cancer, Bristol Myers Squibb, United, Ministry of Education (Malaysia), CD71, CD166, IND, Twitter, EGFR, CD3, LinkedIn, Progression-free survival, Conjugation, Pharmaceutical industry, Video game, Vaccine, Fine chemical, Cryptocurrency

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today reported second quarter 2022 financial results and provided a business update.

Key Points: 
  • A data update for the fully enrolled squamous non-small cell lung cancer cohort is expected in the fourth quarter of 2022.
  • CytomX has prioritized the development of CX-2051 and an IND submission is planned in the second half of 2023.
  • General and administrative expenses increased by $2.4 million during the second quarter of 2022 to $11.7 million.
  • ET (2:00 p.m. PT) to discuss the financial results and provide a business update.

InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China

Retrieved on: 
Tuesday, August 2, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Conditional sentence, IBD, Autoimmune disease, Inflammation, Psoriasis, CEO, IFN, Cardiovascular disease, Inflammatory bowel disease, Signal transduction, Cancer, Quality of life, Clinical trial, Patient, Lupus, Degenerative disease, TYK2, Autoimmunity, HKEX, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Companys TYK2 JH2 allosteric inhibitor ICP-488 in China.

Key Points: 
  • InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in clinical trial of the Companys TYK2 JH2 allosteric inhibitor ICP-488 in China.
  • ICP-488 is a potent and selective TYK2 (tyrosine kinase 2) allosteric inhibitor being developed for the treatment of autoimmune diseases such as psoriasis and inflammatory bowel disease (IBD).
  • Dr. Jasmine Cui, the co-founder, Chairwoman and CEO of InnoCare said, ICP-488 is our third drug candidate entering into the clinic in the field of autoimmune disease.
  • We strategically focus on liquid cancer, solid tumors, and autoimmune diseases with high unmet medical needs in China and worldwide.

CytomX Therapeutics Provides Strategic Update

Retrieved on: 
Wednesday, July 13, 2022
Epithelial cell adhesion molecule, Clinical trial, 23rd Street station (IND Eighth Avenue Line), Safety, Biotechnology, Bi-specific T-cell engager, Program, EGFR, Therapeutic index, Nivolumab, IND, New Drug Application, Therapy, AbbVie, IFN, Company, LinkedIn, TCB, Risk, Organization, United, Conditional, ADC, Patient, SAN, Triple-negative breast cancer, Ipilimumab, GLOBE, COVID-19, Director, Conjugation, Nasdaq, Neoplasm, CD71, Amgen, CD166, Cancer, Research, Twitter, Board, Workforce, CD3, Partnership, Bristol Myers Squibb, Pharmaceutical industry, Vaccine, Fine chemical, Astellas Pharma

SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced plans to focus on its emerging pre-clinical and early clinical pipeline and to realign its capital resources to drive these efforts.

Key Points: 
  • With the Probody therapeutic platform, CytomX has pioneered a new and strategic field of biologics drug discovery and development.
  • CytomX has established strategic collaborations with multiple leaders in oncology, including AbbVie, Amgen, Astellas, and Bristol Myers Squibb.
  • CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
  • Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

IFN Neurologic and MetaCell Partner to Launch the IFN Neurologic Affiliate Program

Retrieved on: 
Tuesday, June 28, 2022
Vertigo, Institute, UCSD, Patient, Research, Brain, COO, UCL, Stroke, Lists of diseases, Depression, Autism, Tic disorder, Migraine, Partnership, Biogen, AICN, Learning, Software, Doctor of Philosophy, Nervous system, Epilepsy, Solution, Australian Institute for Suicide Research and Prevention, Molecular biology, IFN, Web browser, Program, Data science, Multimedia, Online shopping, Pharmaceutical industry, Yale University, Princeton University, Pfizer

This application will help clinicians to better serve patients with neurological disorders and provide treatments in the functional neuroscience domain.

Key Points: 
  • This application will help clinicians to better serve patients with neurological disorders and provide treatments in the functional neuroscience domain.
  • Affiliate clinics will use for the first time IFN Neurologic to perform restorative neuroplasticity interventions on their patients at their own clinic.
  • The affiliate program includes a comprehensive education program accredited by IFN (Institute of Functional Neuroscience) and AICN (Australian Institute of Clinical Neuroscience), all the necessary hardware/software, and access to the IFN Neurologic platform.
  • Dr. Randy Beck, PhD, Director of the IFN, said: "We're excited to be launching this new application in partnership with MetaCell.

IFN Neurologic and MetaCell Partner to Launch the IFN Neurologic Affiliate Program

Retrieved on: 
Tuesday, June 28, 2022
Vertigo, Institute, UCSD, Patient, Research, Brain, COO, UCL, Stroke, Lists of diseases, Depression, Autism, Tic disorder, Migraine, Partnership, Biogen, AICN, Learning, Software, Doctor of Philosophy, Nervous system, Epilepsy, Solution, Australian Institute for Suicide Research and Prevention, Molecular biology, IFN, Web browser, Program, Data science, Pharmaceutical industry, Yale University, Princeton University, Pfizer

This application will help clinicians to better serve patients with neurological disorders and provide treatments in the functional neuroscience domain.

Key Points: 
  • This application will help clinicians to better serve patients with neurological disorders and provide treatments in the functional neuroscience domain.
  • Affiliate clinics will use for the first time IFN Neurologic to perform restorative neuroplasticity interventions on their patients at their own clinic.
  • The affiliate program includes a comprehensive education program accredited by IFN (Institute of Functional Neuroscience) and AICN (Australian Institute of Clinical Neuroscience), all the necessary hardware/software, and access to the IFN Neurologic platform.
  • Dr. Randy Beck, PhD, Director of the IFN, said: "We're excited to be launching this new application in partnership with MetaCell.

Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Pancreatic Cancer

Retrieved on: 
Thursday, June 16, 2022
Pancreas, Interferon, US Food Sovereignty Alliance, FDA, Therapy, IFNAR, Safety, American Cancer Society, MIC, Death, Pancreatic cancer, Tumor microenvironment, CD138, Cancer, ODD, IFN, Investigational New Drug, Immune system, IND, Diana Nammi, IMP, Head, Patient, Toxic epidermal necrolysis, Neoplasm, Toxicity, Colon, Multiple myeloma, Immunotherapy, Breast, Pharmaceutical industry, Vaccine

LOS ANGELES, June 16, 2022 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi), a Los Angeles based immunotherapy company, announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead program, QXL138AM, for the treatment of Pancreatic Cancer.

Key Points: 
  • LOS ANGELES, June 16, 2022 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi), a Los Angeles based immunotherapy company, announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead program, QXL138AM, for the treatment of Pancreatic Cancer.
  • Nammi has previously received ODD for QXL138AM for treatment of multiple myeloma.
  • Pancreatic Cancer is a relatively rare form of cancer, with the American Cancer Society estimating over 62,210 new cases and 49,830 deaths from Pancreatic Cancer this year.
  • Nammi Therapeutics is expecting to file an Investigational New Drug (IND) application with the FDA to allow initiation of clinical studies this year.

Nammi Therapeutics Granted FDA Orphan Drug Designation For QXL138AM for the Treatment of Multiple Myeloma

Retrieved on: 
Monday, June 13, 2022
American Cancer Society, Interferon, Death, Head, Survival, Neoplasm, US Food Sovereignty Alliance, Toxicity, Diana Nammi, Multiple myeloma, CD138, IFNAR, Investigational New Drug, Reproductive toxicity, Therapy, ODD, IND, Breast, FDA, IMP, Tumor microenvironment, Immune system, Colon, MIC, IFN, Cancer, Safety, Pharmaceutical industry, Vaccine

LOS ANGELES, June 13, 2022 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi), an LA-based immunotherapy company, announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead program, QXL138AM, for the treatment of multiple myeloma.

Key Points: 
  • LOS ANGELES, June 13, 2022 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi), an LA-based immunotherapy company, announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead program, QXL138AM, for the treatment of multiple myeloma.
  • Activation of the IFNAR complex induces direct killing of myeloma cells as well as activating innate and adaptive anti-tumor immunity.
  • Multiple Myeloma is a relatively rare form of cancer, with the American Cancer Society estimating over 34,000 new cases and 12,000 deaths from multiple myeloma this year.
  • Nammi Therapeutics is expecting to file an Investigational New Drug (IND) application with the FDA to allow initiation of clinical studies this year.